WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica

WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica

Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo

11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeu

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeu

SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Cellares, the first Integrated Develo

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.22 per share in line with the Z

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.22) per share which missed the ana

Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinic

Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform a

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks C

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.18) per share which beat the analy

Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of He

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercia

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercia

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica

TScan Therapeutics, Inc. (NASDAQ: TCRX - Get Free Report) has received an average rating of "Hold" f

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo

Treatment arm continues to demonstrate favorable relapse-free survival (HR=0. 50; p=0. 23) and overa

/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia eliminat

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica

HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) wi

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks C

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analy

Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 m

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinica

Needham analyst Gil Blum maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the pri

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the develo

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analys

HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with

TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.26) per share which beat the analy

Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $9

Barclays analyst Peter Lawson maintains TScan Therapeutics (NASDAQ:TCRX) with a Overweight and lo